All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
In November 2017, Paolo Strati of the MD Anderson Cancer Center in Houston, Texas and colleagues published online [article in press] in Clinical Lymphoma, Myeloma & Leukemia, a long-term, observational case series of 45 patients with follicular lymphoma grade 3 (FLG3) who had been treated with frontline rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). By closely examining their long-term outcomes, the authors sought to determine an optimal treatment/disease management strategy for this otherwise controversial group of patients.
While FLG3 represents approximately 30% of FLs and 6% of all lymphomas, some controversy exists that has focused on whether FLG3 should be grouped with DLBCL rather than a discreet grade of FL. The authors had previously published a different iteration of this case series of 45 patients with FLG3 who received frontline R-CHOP at a single institution, which showed a high ORR and improved survival, when compared to a historical group of patients who received CHOP-like regimens that did not include rituximab. They chose to focus on these patients because they are not commonly included in clinical trials or their outcome is often not reported separately. The long-term follow up of these patients has shown, the authors conclude, that R-CHOP is an effective frontline treatment for patients with FLG3, underscored by the 3-year PFS of 70%, in addition to ORR and CR rates of 100% and 96%, respectively.
The optimal management of patients with follicular lymphoma grade 3 (FLG3) is controversial. This is a case series of 45 patients with FLG3 treated with frontline R-CHOP and observed for an extended time interval. The overall response rate was 100% and the median progression-free survival (PFS) has not been reached, with a 3-year PFS of 70%; 14 (31%) patients relapsed, nearly all within 3 years. The baseline characteristic more strongly associated with a shorter PFS were lymph node sites more than 4 and presence of B symptoms. Three patients later progressed to DLBCL, all had baseline elevated serum LDH and high IPI score. Median overall survival (OS) has not been reached. All 4 patients who later developed AML were older than 60 at the time of start of therapy. R-CHOP is an effective frontline treatment for patients with FLG3, and may provide extended PFS, comparable to outcomes observed in diffuse large B-cell lymphoma, particularly in subgroups with limited nodal disease.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox